Implementation blood biomarkers in clinical practice and trials, Chair: Stephen Salloway, Brown University – Providence (United States)
1. Defining the minimum acceptable performance of blood-based biomarkers of Alzheimer’s disease for clinical use in symptomatic patients, Suzanne Schindler, Washington University School of Medicine – St. Louis (United States)
2. A highly accurate blood test for Alzheimer’s disease pathology has performance equivalent or superior to clinically used cerebrospinal fluid tests, Oskar Hansson, Lund University – Lund (Sweden)
3. Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s Disease, Robert Rissman, Alzheimer, University California San Diego – San Diego (United States)
